Cefuroxime axetil

From Wikipedia, the free encyclopedia

Cefuroxime axetil
Clinical data
Trade namesZinnat, Ceftin, Ceftum
Other namesCefuroxime 1-acetoxyethyl ester
AHFS/Drugs.comMonograph
MedlinePlusa601206
Routes of
administration		By mouth, intravenous, intramuscular
ATC code
  • None
Legal status
Legal status
Pharmacokinetic data
Bioavailabilitywell absorbed
MetabolismCefuroxime is not metabolized and excreted as it is in urine, axetil is metabolized to acetaldehyde and acetic acid[medical citation needed]
ExcretionUrine
Identifiers
  • 1-Acetoxyethyl (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-(2-furyl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.166.374 Edit this at Wikidata
Chemical and physical data
FormulaC20H22N4O10S
Molar mass510.47 g·mol−1
3D model (JSmol)
  • O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3occc3)COC(=O)N)C(=O)OC(OC(=O)C)C
  • InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1
  • Key:KEJCWVGMRLCZQQ-YJBYXUATSA-N

Cefuroxime axetil, sold under the brand name Ceftin among others, is a second generation oral cephalosporin antibiotic.

It is an acetoxyethyl ester prodrug of cefuroxime which is effective orally.[2] The activity depends on in vivo hydrolysis and release of cefuroxime tablets.[citation needed]

It was patented in 1976 and approved for medical use in 1987.[3]

Medical uses[edit]

Second generation cephalosporins are more effective in treating Gram-negative bacilli compared to first generation cephalosporins, which have a greater coverage for Gram-positive cocci. Also, it has been reported that cefuroxime is resistant to hydrolysis by β-lactamases produced by Gram-negative bacteria.[4]

Some medical uses are:[5][6]

Bacterial susceptibility[edit]

Cefuroxime axetil treats infections against methicillin, oxacillin and penicillin-sensitive bacterial strains.[7] Cefuroxime axetil does not work against enterococci. [5]

Gram-positive aerobic microorganisms

Gram-negative aerobic microorganisms

Mechanism of action[edit]

Cefuroxime axetil is a second generation cephalosporin that, like penicillins antibiotics, contains a β-lactam ring structure. Cephalosporins work as bactericidal antibiotics; that by binding to penicillin-binding proteins (PBPs), inhibit the last step of the bacterial cell wall synthesis. Once the β-lactam ring binds to PBPs, cross-linking between peptidoglycan units is inhibited.[4]

Pharmacokinetics[edit]

Absorption: Once consumed, cefuroxime axetil is converted to the active compound cefuroxime by esterases of mucosal cells in the gastrointestinal tract. Cefuroxime is then released for systematic circulation. If cefuroxime axetil is given with food, absorption values can increase by 52% compared to fasting patients.[5]

Distribution: It has been reported that after cefuroxime axetil administration, it can be found in tonsil tissue, sinus tissue, bronchial tissue and middle ear effusion.[5]

Elimination: After cefuroxime production, the body is unable to metabolize the drug, and is eliminated unchanged in the urine.[5]

History[edit]

It was discovered by Glaxo (now GlaxoSmithKline) and introduced in 1987.[8] It was approved by FDA on December 28, 1987.[9] It is available by GSK as Ceftin in US[10] and Ceftum in India.[11]

References[edit]

  1. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  2. ^ Sneader W (23 June 2005). Drug Discovery: A History. John Wiley, Chichester, UK. ISBN 0-471-89979-8.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 494. ISBN 9783527607495.
  4. ^ a b Bui T, Preuss CV (2020). "Cephalosporins". StatPearls. StatPearls Publishing. PMID 31855361. Retrieved 23 April 2020.
  5. ^ a b c d e Perry CM, Brogden RN (July 1996). "Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy". Drugs. 52 (1): 125–158. doi:10.2165/00003495-199652010-00009. PMID 8799689. S2CID 46985101.
  6. ^ "Ceftin (cefuroxime axetil)" (PDF). GlaxoSmithKline. U.S. Food and Drug Administration. 2015. Retrieved 22 April 2020.
  7. ^ "Zinnat SUMMARY OF PRODUCT CHARACTERISTICS - GSKPro for Healthcare Professionals" (PDF).
  8. ^ "Our history - About GSK". GlaxoSmithKline. Archived from the original on 14 May 2011.
  9. ^ "Cefuroxime Axetil Monograph for Professionals". Drugs.com. Retrieved 22 April 2018.
  10. ^ "Brands". Gsksource.com. 22 March 2018. Archived from the original on 20 March 2016. Retrieved 22 April 2018.
  11. ^ "Our products". GlaxoSmithKline. Archived from the original on 22 March 2016. Retrieved 12 March 2012.

External links[edit]

"Cefuroxime Injection: MedlinePlus Drug Information". MedlinePlus.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Cefuroxime_axetil&oldid=1216427836"